Early detection of subclinical left ventricular dysfunction after breast cancer radiation therapy using speckle-tracking echocardiography: association between cardiac exposure and longitudinal strain reduction (BACCARAT study)

Valentin Walker¹, Olivier Lairez², Olivier Fondard³, Atul Pathak³, Baptiste Pinel⁴, Christian Chevelle⁴, Denis Franck⁴, Gaëlle Jimenez⁴, Jérémy Camilleri⁴, Loïc Panh⁵, David Broggio⁶, Sylvie Derreumaux⁷, Marie-Odile Bernier¹, Dominique Laurier⁷, Jean Ferrières⁸,⁹ and Sophie Jacob¹*

Abstract

Background: Breast cancer (BC) radiotherapy (RT) can induce cardiotoxicity, with adverse events often observed many years after BC RT. Subclinical left ventricular (LV) dysfunction can be detected early after BC RT with global longitudinal strain (GLS) measurement based on 2D speckle-tracking echocardiography. This 6-month follow-up analysis from the BACCARAT prospective study aimed to investigate the association between cardiac radiation doses and subclinical LV dysfunction based on GLS reduction.

Methods: The patient study group consisted of 79 BC patients (64 left-sided BC, 15 right-sided BC) treated with RT without chemotherapy. Echocardiographic parameters, including GLS, were measured before RT and 6 months post-RT. The association between subclinical LV dysfunction, defined as GLS reduction > 10%, and radiation doses to whole heart and the LV were performed based on logistic regressions. Non-radiation factors associated with subclinical LV dysfunction including age, BMI, hypertension, hypercholesterolemia and endocrine therapy were considered for multivariate analyses.

(Continued on next page)
Background
Breast cancer (BC) radiotherapy (RT) reduces BC recurrence and improves survival [1]. However, increased risk of cardiac death many years after BC RT has been documented [2]. For long-term radiotherapy-induced cardiac complications, dose-response relationships between the mean heart dose and the rate of major coronary events were observed [3–5]. Long before the onset of clinically relevant cardiac events, evaluation of early myocardial dysfunction was investigated after BC RT [6]. This was based on two-dimensional speckle tracking echocardiography (2DSTE) that has allowed accurate measurements of global and regional myocardial deformation with strain [7, 8]. Several studies have showed the higher sensitivity and prognostic value of the global longitudinal strain (GLS), compared with left ventricular ejection fraction (LVEF), for early detection of left ventricular dysfunction, and it has been shown that detecting a decreased LVEF after RT may be too late for treatment [9, 10].

In most of previous studies on early myocardial dysfunction post BC RT, a statistically significant decrease in GLS was observed among left-sided BC patients, ranging from 5 to 14% at different post-RT time points from few weeks to 14 months [11–16], whereas no measurable alteration of LVEF was observed. However, in these studies, no or few results were specifically presented for patients with a drop in GLS > 10% whereas this threshold is considered to define subclinical left ventricular dysfunction and has been reported to be predictive of subsequent cardiotoxicity [17, 18].

Knowledge on the relationship between cardiac exposure and the decrease of strain is limited. A dose-related regional myocardial dysfunction in the acute phase after RT was found in left-sided BC patients with the greatest reduction in the apical part of the left ventricle, which received the highest radiation dose [15], but no significant association was found between the mean heart dose and the GLS reduction [19]. Further studies are needed to investigate the association between cardiac exposure and the evolution of GLS after RT, considering in particular the doses absorbed to the whole heart as well as to cardiac substructures such as the left ventricle or the coronary arteries. Indeed, these doses could enhance knowledge on the dose-response relationship according to the type of cardiotoxicity and its location [20].

Based on the BACCARAT prospective cohort of BC patients treated with 3D-CRT (3-Dimensional Conformal Radiotherapy), we aimed to present a 6-month follow-up analysis of the association between radiation exposure to the whole heart and the left ventricle (LV) and the evolution of GLS from baseline to 6 months after RT, in particular for subclinical LV dysfunction defined as GLS reduction > 10%, a secondary endpoint of BACCARAT.

Results: A mean decrease of 6% in GLS was observed (−15.1% ± 3.2% at 6 months vs. −16.1% ± 2.7% before RT, p = 0.01). For left-sided patients, mean heart and LV doses were 3.1 ± 1.3 Gy and 6.7 ± 3.4 Gy respectively. For right-sided patients, mean heart dose was 0.7 ± 0.5 Gy and median LV dose was 0.1 Gy. Associations between GLS reduction > 10% (37 patients) and mean doses to the heart and the LV as well as the V20 were observed in univariate analysis (Odds Ratio = 1.37 [1.01–1.86], p = 0.04 for Dmean Heart; OR = 1.14 [1.01–1.28], p = 0.03 for Dmean LV; OR = 1.08 [1.01–1.14], p = 0.02 for LV V20). In multivariate analysis, these associations did not remain significant after adjustment for non-radiation factors. Further exploratory analysis allowed identifying a subgroup of patients (LV V20 > 15%) for whom a significant association with subclinical LV dysfunction was found (adjusted OR = 3.97 [1.01–15.70], p = 0.048).

Conclusions: This analysis indicated that subclinical LV dysfunction defined as a GLS decrease > 10% is associated with cardiac doses, but adjustment for non-radiation factors such as endocrine therapy lead to no longer statistically significant relationships. However, LV dosimetry may be promising to identify high-risk subpopulations. Larger and longer follow-up studies are required to further investigate these associations.

Trial registration: ClinicalTrials.gov: NCT02605512, Registered 6 November 2015 - Retrospectively registered

Keywords: Breast Cancer, 3D conformal radiation therapy, Cardiac dysfunction, Strain imaging, Cardiac Dosimetry

Materials and methods
Patient population
This prospective, monocentric observational clinical study [21] initially included 118 female patients of the Clinic Pasteur Toulouse from October 2015 to December 2017, aged 40 to 75 years old, mainly with left unilateral BC, and in a smaller proportion with right-sided unilateral BC, followed from baseline before RT to 6 months after RT. All patients were treated with adjuvant 3D-CRT after breast conserving surgery or mastectomy, without chemotherapy. Five patients withdrew consent and 8 patients had abnormal LVEF before RT (LVEF < 45%). For this analysis, we excluded all echocardiographies for which the image quality was too low for a reliable assessment of...
longitudinal strain ($n = 20$). In addition, 6 patients without available cardiac dosimetry (see details below) were excluded. Finally, the patient study group consisted of 79 patients.

**Radiotherapy treatment**

After the surgical treatment of BC, all patients were treated with 3D-CRT with 6 and 25 MV photon beams by tangential fields. The planning target volume dose was 50 Gy delivered in 25 daily fractions of 2 Gy over 5 weeks or 47 Gy delivered in 20 daily fractions of 2.35 Gy over 5 weeks for patients treated between January 2016 and May 2016 (technical problems arose in one 3D-CRT machine during this period and this hypofractionation choice was only driven by the need to slightly limit the number of sessions per patient). For most patients, 6MV photons were used, except few cases of patients with big breast where 25 MV additional photons were used. Additional boost of 9–15 Gy could be applied to the tumor site using photon/electron beams with energies ranging from 6 MeV to 18 MeV. The treatment planning system (TPS) used to perform dose calculations was Eclipse™ from Varian Medical System (Palo Alto, CA, USA). Each patient’s RT was planned such that the dose distribution was optimized and normalized to the International Commission on Radiation Units and Measurements (ICRU) reference point of the breast and to achieve QUANTEC dose constraints to organs at risk including the heart [22].

**Evaluation of radiation doses**

The methodology of the complete evaluation of radiation doses in BACCARAT patients was previously described [20, 21]. Only whole heart and left ventricle were considered in the analyses presented here. Dose-Volume-Histogram (DVH) for the heart was generated by the Clinic Pasteur RT department. Manual delinea- tion of the left ventricle was performed. Using the 3D dose matrix generated during planning treatment and the new delineated substructure, DVH for LV was generated with ISOGray TPS by the dosimetric department of IRSN in collaboration with the Clinic Pasteur RT department. From the DVHs, the following absorbed dose metrics for whole heart and left ventricle were calculated: $D_{\text{mean}}$ (in Gy) is the volume-weighted mean dose; $D_2$ (in Gy) is the minimal dose received by the most irradiated 2% of the structure volume, which can be considered as the near maximum dose; $V_{20}$ (in %) is the relative volume exposed to at least 20 Gy.

**Echocardiographic examinations**

A comprehensive 2D echocardiography study was performed at baseline before RT and 6 months after RT with a commercially available ultrasound Acuson S2000 (Siemens Medical Solutions USA, Inc. Malvern, USA), using a 3 MHz transducer. Image analysis was independently performed by a single blinded observer unaware of clinical data. LV ejection fraction (LVEF) was measured using the biplane Simpson’s method from apical two- and four-chamber windows. Myocardial function by longitudinal myocardial strain was calculated using two-dimensional speckle tracking echocardiography (2DSTE) and the automated function imaging technique for tracking of acoustic markers (speckles) [23]. The 2DSTE vendor offline Syngo Velocity Vector Imaging 2.0 software (Siemens Medical Solutions USA, Inc., Mountain View, Calif, USA) was used. Images were analyzed in a 16-segment model according to the American Society of Echocardiography guidelines [24]. Moreover, the LV wall is not homogenous and includes an endocardial, a mid-myocardial, and an epicardial layer [25]. There are concurrent definitions as a basis for GLS calculation using endocardial, midwall, epicardial or average deformation. Measures of midwall longitudinal strain have been shown in several studies to be robust and reproducible [24] and for this analysis, we considered on the mid-myocardial layer for strain and strain rate. All segmental values were averaged to Global Longitudinal Strain (GLS, in %) and Global Longitudinal Strain Rate (GLSR, in s$^{-1}$).

**Statistical analysis**

Continuous variables are presented with mean and standard deviation or median and (interquartile) range values. Categorical values are presented with percentages. Student’s $t$-test or Wilcoxon non-parametric test was used to compare continuous variables, adapted to paired samples for the comparison of echocardiographic variables (LVEF, GLS, GLSR) before RT and 6 months after RT. Percent change in GLS was defined as the ratio of the difference between RT + 6 months measurement and baseline measurement. A more than 10% decrease in the GLS is generally considered clinically relevant [16–18] to detect subclinical left ventricular dysfunction. For whole heart and left ventricle, we considered the following dosimetric parameters: $D_{\text{mean}}$, $D_2$ (in Gy), and $V_{20}$ (in %). The continuous association between dose measures and GLS change was illustrated with scatter plots with a non-parametric smooth (Lowess method). Comparison of the dosimetric parameters between the group GLS reduction > 10% and GLS reduction ≤10% was performed. In order to take into account multiple testing in these comparisons, we applied the Holm–Bonferroni method, a step-down procedure performed after conducting the 6 comparison tests. We analyzed the associations between GLS reduction > 10% and radiation and non-radiation factors in univariate analysis based on
logistic regressions which provided odds ratios (OR). Cardiac radiation factors included the laterality of BC, Dmean, D2 and V20 of the heart and the left ventricle. Non radiation factors included age, BMI, smoking status, hypertension, diabetes, hypercholesterolemia and endocrine therapy. We also tested the association with the prescribed RT fractionation. For multivariate analysis, we only considered non-radiation variables with p-value < 0.20 in univariate analysis. Finally, p-value < 0.05 was considered statistically significant. All statistical analysis was performed using SAS statistical software for Windows (Version 9.4 – SAS Institute, Cary, NC).

Results

Study population
A total of 79 BC patients (64 left-sided and 15 right-sided) were included in the analysis. Baseline patients’ characteristics are shown in Table 1. The mean age was 58 ± 9 years. Most patients (84%) were diagnosed with an invasive ductal carcinoma, underwent breast conserving surgery (97%) and received endocrine therapy (76%). The prescribed radiation dose was 50 Gy in 25 sessions for 75% of the population. Concerning cardiac risk factors, 24% of the patients had hypertension and 30% hypercholesterolemia. No significant differences in these characteristics were observed between left-sided and right-sided BC patients (data not shown).

Cardiac doses
Radiation doses received by the heart and the left ventricle are detailed in Table 2. For left-sided patients, mean heart dose and mean LV dose were respectively 3.05 ± 1.31 Gy and 6.68 ± 3.36 Gy. Doses were much lower among right-sided patients. Half of left-sided patients received doses higher than 20 Gy to a volume of LV > 10%.

Echocardiographic findings
The results of echocardiography are summarized in Table 3. Compared with baseline pre-RT, no significant decrease in either LVEF or GLSR was observed. However, the GLS was significantly lower 6 months after RT at least for left-sided patients (~ 16.0 ± 2.6% at baseline vs. -15.0 ± 3.0% at RT + 6 months, p = 0.02) with a mean decrease of 6%. We observed subclinical LV dysfunction defined as GLS reduction > 10% in 37 patients corresponding to 48% of left-sided BC patients and 40% of right-sided BC patients. Moreover, 18 patients with a GLS increase > 10% were observed (27% among right-sided BC patients and 21% among left-sided BC patients).

| Table 1 Baseline characteristics of the study population: demographic, tumor and treatment cardiovascular history |
|---------------------------------------------------------------|
| **All patients**                                               |
| **N** = 79                                                      |
| Age in years, mean ± SD 58 ± 9                                 |
| Left-sided BC patients                                          |
| Type of cancer, n (%)                                          |
| In situ 13 (16%)                                                |
| Invasive 66 (84%)                                               |
| Grade, n (%)                                                    |
| 1 33 (42%)                                                     |
| 2 37 (47%)                                                     |
| 3 9 (11%)                                                      |
| Surgery, n (%)                                                 |
| Breast conserving 76 (96%)                                    |
| Mastectomy 3 (4%)                                              |
| RT protocol, n (%)                                             |
| Standard - 50 Gy 59 (75%)                                     |
| Hypo-fractionated - 47 Gy 20 (25%)                             |
| Boost, n (%)                                                   |
| 75 (95%)                                                       |
| Regional lymph node irradiation, n (%)                         |
| Supraclavicular alone 2                                         |
| Internal mammary alone 2                                       |
| Both 19                                                        |
| Endocrine therapy, n (%)                                       |
| Anti-aromatase 34                                               |
| Tamoxifen 26                                                    |
| Body mass index in kg/m², mean ± SD 24.4 ± 4.1                 |
| Smoking, n (%)                                                 |
| Never-smokers 42 (53%)                                        |
| Former smokers 23 (29%)                                        |
| Current smokers 14 (18%)                                      |
| Systolic blood pressure, in mmHg, mean ± SD 119 ± 13           |
| Diastolic blood pressure in mmHg, mean ± SD 74 ± 10            |
| Hypertension, n (%)                                            |
| 19 (24%)                                                       |
| Diabetes, n (%)                                                |
| 5 (6%)                                                         |
| Hypercholesterolemia, n (%)                                    |
| 24 (30%)                                                       |

**BC** Breast Cancer, **RT** Radiotherapy, **SD** Standard Deviation

Associations between GLS reduction > 10% and radiation and non-radiation factors
As illustrated in Fig. 1, no continuous association between dose measures and GLS change was observed with Spearman correlation coefficients between −0.03 and −0.10. The comparison of cardiac doses between patients with subclinical LV dysfunction (GLS reduction > 10%) and those without dysfunction (GLS reduction ≤10%) showed higher doses in heart or LV for patients with GLS reduction > 10%, in particular.
for LV V20 (11.1% vs. 6.6%) (Fig. 2). After Holm-Bonferroni method for multiple testing, none of these differences reached statistical significance. Among non-radiation factors associated with GLS reduction > 10%, BMI, hypercholesterolemia and endocrine therapy reached a p-value of less than 0.20 and were considered in further analysis (Table 4). The significant association with endocrine therapy (OR = 3.20 (1.02–13.03), p = 0.04), was in particular significant for patients treated with anti-aromatase (OR = 4.52 (1.32–15.53)). In univariate analysis, laterality of BC was not significantly associated with the event GLS reduction > 10% (p = 0.55), in contrast with mean dose to the heart and to the left ventricle (Table 5): Odds Ratio = 1.37, p = 0.04 for Dmean Heart; OR = 1.14, p = 0.03 for Dmean LV. Furthermore, an association was observed for LV V20 (OR = 1.08, p = 0.02). In multivariate analysis, none of these associations remained significant after adjustment for BMI, hypercholesterolemia and endocrine therapy. The LV V20 was the closest from statistical significance (OR = 1.05 [0.99–1.12], p = 0.12). In further exploratory analysis of the LV V20, patients were grouped according to whether the LV V20 was 0%, less than 15%, or 15% or more. There was a 4-fold increase in the adjusted odds ratio for subclinical LV dysfunction for the most exposed category, as compared with the 0% category (OR = 3.97 [1.01–15.74], p = 0.048) (Fig. 3).

**Table 2** Radiation doses to the heart and the left ventricle

|                      | Left-sided BC patients | Right-sided BC patients |
|----------------------|------------------------|-------------------------|
|                      | N = 64                 | N = 15                  |
| Mean ± SD            | Median (Q1-Q3)         | Mean ± SD               |
|                      | Range                  | Median (Q1-Q3)          |
|                      |                        | Range                   |
| **Heart**            |                        |                        |
| Dmean (Gy)           | 3.05 ± 1.31            | 0.87–6.37               |
|                      | 0.65 ± 0.49            | 0.25–2.17               |
| D2 (Gy)              | 28.60 ± 16.85          | 4.16–48.87              |
|                      | 2.57 ± 1.16            | 1.11–5.40               |
| V20 (% )             | 3 (1–6)                | 0–10                    |
|                      | 0                      | 0                       |
| **Left Ventricle**   |                        |                        |
| Dmean (Gy)           | 6.68 ± 3.36            | 1.16–13.42              |
|                      | 0.09 (0.08–0.12)       | 0.06–1.24               |
| D2 (Gy)              | 36.28 ± 14.81          | 4.49–55.48              |
|                      | 0.38 (0.29–0.45)       | 0.22–2.53               |
| V20 (% )             | 11 (4–18)              | 0–26                    |
|                      | 0                      | 0                       |

**Table 3** Echocardiographic measurements at baseline and 6 months after RT

|                      | All BC patients N = 79 | Left-sided BC patients N = 64 | Right-sided BC patients N = 15 |
|----------------------|------------------------|-------------------------------|--------------------------------|
| **LVEF (in %)**      |                        |                               |                                |
| Before RT            | 62 ± 7                 | 61 ± 7                        | 64 ± 8                         |
| RT + 6 months        | 60 ± 9                 | 60 ± 9                        | 63 ± 8                         |
| p-value              | 0.07                   | 0.09                          | 0.51                           |
| **GLS (in %)**       |                        |                               |                                |
| Before RT            | -16.1 ± 2.7            | -16.0 ± 2.6                   | -16.2 ± 2.8                    |
| RT + 6 months        | -15.1 ± 3.2            | -15.0 ± 3.0                   | -15.2 ± 4.0                    |
| p-value              | **0.01**               | **0.02**                      | **0.02**                       |
| Patients with GLS reduction <10% after RT | 37 (47%)       | 31 (48%)                      | 6 (40%)                        |
| **GLSR (in s⁻¹)**    |                        |                               |                                |
| q Before RT          | -0.93 ± 0.14           | -0.92 ± 0.15                  | -0.98 ± 0.11                   |
| RT + 6 months        | -0.98 ± 0.21           | -0.96 ± 0.16                  | -1.06 ± 0.34                   |
| p-value              | 0.09                   | 0.15                          | 0.37                           |

**Note:** BC Breast Cancer, SD Standard Deviation, D2 (in Gy): Minimal dose received by the most irradiated 2% of the structure volume; Dmean: Mean dose to the structure; V20 (in %): Relative volume of the structure exposed to at least 20 Gy.

**Discussion**

In this prospective study, we evaluated the association between cardiac exposure and subclinical LV dysfunction defined as GLS reduction >10% from baseline before RT to 6 months after RT in BC patients treated with 3D-CRT without chemotherapy. The associations with mean doses to the heart and the LV as well as the heart and LV V20 were significant in univariate analysis. In multivariate analysis, these associations were no longer significant after adjustment for non-radiation factors including BMI, hypercholesterolemia and endocrine therapy. Further exploratory analysis allowed identifying a subgroup of patients (LV V20 >15%) with a significant association with subclinical LV dysfunction which remained significant after adjustment.

Decrease in longitudinal strain was previously observed in left-sided BC patients with follow-up ranging from few days to 14 months after RT [11, 14, 15, 26] and mean relative decrease in longitudinal strain ranging from 5% to nearly 15% [12]. In our study, the mean decrease of GLS was 6% at 6 months after RT, in the range of previously observed decreases. The absence of significant decrease of GLS in right-sided BC patients was also previously observed in these studies even if the limited size of right-sided BC patients group could partly explain these non-significant results. Similarly to most other previous studies [12–15, 26], no significant decrease in LVEF was observed at RT + 6 months in our patients compared with pre-RT.

We considered a subclinical LV dysfunction defined as GLS reduction >10% which has been considered clinically relevant [18] and which was also considered in other previous studies [17, 27]. This early index of cardiotoxicity was observed in 48% of our left-sided BC patients 6 months after RT, which is higher than the 28% observed elsewhere with a shorter follow-up limited to end of RT.
Such subclinical dysfunction may need longer follow-up to develop. No other study evaluated the frequency of this subclinical event as they mainly considered the GLS as a continuous variable which may limit the clinical implication and applications.

Even if all previous studies concluded that longitudinal strain was decreased after RT for left-sided BC patients and not for right-sided BC patients, little was known on the association between cardiac doses and decrease in longitudinal strain. A modest correlation was observed between GLS reduction 6 weeks after RT and mean heart dose or V30 ($R = 0.35$, $R = 0.22$) [26, 27], but no difference in radiation dose between the group with or without a > 10% reduction in GLS was observed. That could be explained by the limited number of patients and also the potential contribution of factors apart from radiation dose [16]. With a very short follow-up (end of RT), another study did not find an association between mean heart dose and the mean GLS reduction [14]. In our study, we observed significant associations between cardiac doses and subclinical LV dysfunction defined as GLS reduction > 10%. However, these associations were no longer significant after adjustment for non-radiation factor also associated with subclinical LV dysfunction including BMI, hypercholesterolemia and endocrine therapy. It was interesting to note that LV exposure, in particular V20 of the LV, was associated with subclinical LV dysfunction. As exploratory analysis, we identified a subgroup of patients with LV V20 > 15% and there was for this group a 4-fold increase in the adjusted odds ratio for subclinical LV dysfunction, as compared with the 0% category. This may be an indication for future research investigating strain evolution post-RT and subclinical LV dysfunction: instead of whole heart doses, analysis of LV exposure may provide better information to understand the association with RT. In a previous work published by Van Den Bogaard et al. [5], an association between the volume of the left ventricle receiving 5 Gy (LV-V5) and cumulative incidence of acute coronary event (ACE) was observed. Their analysis showed that LV-V5 was the most important prognostic dose-volume parameter. In our study, LV-V5 was significantly associated with GLS reduction > 10% in univariate analysis (OR = 1.04 [1.00–1.08], $p = 0.04$) but was no longer significant in multivariate analysis (OR = 1.03 [0.99–1.07], $p = 0.21$).
Contribution of factors apart from radiation dose on the risk of long term cardiac disease, such as age, hypertension, diabetes or preexisting cardiac diseases was previously observed [3] as they had an additive effect on the risk of cardiac disease. At the scale of subclinical LV dysfunction, quantified by longitudinal strain, it was also important to consider their contribution on the associations. Among the different factors that we considered, endocrine therapy was associated with subclinical LV dysfunction (OR = 3.20, 95% CI (1.02–10.10)), in particular for aromatase inhibitors (OR = 4.25, 95% CI (1.32–15.53)) which are known risk factors for cardiovascular disease [28]. An independent association between a reduction in GLS and the use of aromatase inhibitors was also previously observed [14]. The BMI was also important to consider in multivariate analysis, as it was a confounding factor: associated with both the cardiac event and the dose. We observed that patients with higher BMI had higher cardiac doses (Heart Dmean = 2.1 Gy for patient with BMI < 25 kg/m^2 vs. 3.3 Gy for patients with BMI > 25 kg/m^2, p < 0.01), as previously observed [29]. Last, the cardiotoxicity of chemotherapy, such as anthracyclines or trastuzumab, are known to alter the longitudinal strain [30, 31]. A strength of our study was to include chemotherapy-naïve patients, which allowed a precise evaluation of the association with radiation exposure without confounding due to chemotherapy.

**Fig. 2** Boxplots for the distribution of heart and left ventricle (LV) doses and V20 according to the category without or with subclinical LV dysfunction (GLS reduction ≤10% and >10% respectively). * after Holm-Bonferroni methods for multiple testing, these p-values were no longer significant (n.s.)
diography of our patients and will further analyze this. Now collecting strain segmental values for each echocardiogram may be heterogenous in cardiac territories, and vascular exposure [20] may be significant for regional myocardial dysfunction in the acute phase after RT [11].

However, we are now collecting strain segmental values for each echocardiogram of our patients and will further analyze this data according to the precise individual dose evaluation of each coronary artery [20]. On the other side, the strain is not uniform over the LV. The LV wall is not homogenous and comprises an endocardial, a mid-myocardial, and an epicardial layer [25]. Recent 2DSTE software allows separate evaluation of myocardial layers deformation [33]. Our measurements of longitudinal strain focused on individual evaluation of midwall deformations. Our results at baseline (GLS = −16.1 ± 2.7%) is consistent with the GLS observed in previous study [34].

Some studies investigated more precisely the longitudinal strain changes based on the segmental evaluation within the LV [32]. Lo et al. detected dose-related regional myocardial dysfunction in the acute phase after RT with the greatest reduction in the apical part of the LV, which received the highest radiation dose [15]. In the Erven’s study [11], changes were more pronounced in the LV wall receiving the highest RT dose (anterior wall). Heterogeneity of cardiac exposure [20] may be considered for precise evaluation of cardiotoxicity with the assessment of doses to cardiac substructures such as LV or LAD. The LV segmentations and assignment of these segments to coronary arterial territories are still not sharply defined and confusing [32]. However, we are now collecting strain segmental values for each echocardiography of our patients and will further analyze this

Table 4 Non radiation factors associated with subclinical LV dysfunction (GLS reduction > 10%) after RT

|                  | OR (95% CI)       | p-value |
|------------------|-------------------|---------|
| Age (in years)   | 0.98 (0.93–1.04)  | 0.52    |
| BMI (in Kg.m⁻²)  | 1.15 (1.02–1.30)  | 0.02a   |
| Smoking          |                   |         |
| Former vs. No    | 0.59 (0.20–1.68)  | 0.31    |
| Current vs No    | 1.98 (0.57–6.91)  | 0.28    |
| Hypertension     | 1.03 (0.37–2.89)  | 0.95    |
| Diabetes         | 1.76 (0.28–11.19) | 0.55    |
| Hypercholesterolemia | 1.95 (0.74–5.15) | 0.18a   |
| Endocrine therapy| 3.20 (1.02–10.10) | 0.04a   |
| Anti-aromatase   | 4.52 (1.32–15.53) | 0.02    |
| Tamoxifen        | 2.05 (0.57–7.41)  | 0.27    |
| RT protocol (hypofractionnated vs. standard) | 0.91 (0.33–2.51) | 0.84 |

Table 5 Associations between cardiac radiation doses and subclinical LV dysfunction (GLS reduction > 10%) after RT

|                  | Univariate analysis | Multivariate analysis* |
|------------------|---------------------|------------------------|
|                  | OR (95% CI)         | p-value                | OR (95% CI) | p-value |
| Latexeterity of BC (left vs. right) | 1.41 (0.45–4.42) | 0.55                   | –           | –       |
| Heart            |                     |                        |             |         |
| Dmean (Gy)       | 1.37 (1.01–1.86)    | 0.04                   | 1.21 (0.87–1.71) | 0.26 |
| D2 (Gy)          | 1.02 (0.99–1.05)    | 0.13                   | –           | –       |
| V20 (%)          | 1.20 (1.01–1.43)    | 0.04                   | 1.13 (0.93–1.36) | 0.23 |
| Left Ventricle   |                     |                        |             |         |
| Dmean (Gy)       | 1.14 (1.01–1.28)    | 0.03                   | 1.09 (0.96–1.25) | 0.17 |
| D2 (Gy)          | 1.02 (0.99–1.04)    | 0.22                   | –           | –       |
| V20 (%)          | 1.08 (1.01–1.14)    | 0.02                   | 1.05 (0.99–1.12) | 0.12 |

*Adjusted for BMI, hypercholesterolemia and endocrine therapy; p-values in bold are significant (<0.05)

Some studies investigated more precisely the longitudinal strain changes based on the segmental evaluation within the LV [32]. Lo et al. detected dose-related regional myocardial dysfunction in the acute phase after RT with the greatest reduction in the apical part of the LV, which received the highest radiation dose [15]. In the Erven’s study [11], changes were more pronounced in the LV wall receiving the highest RT dose (anterior wall). Heterogeneity of cardiac exposure [20] may be considered for precise evaluation of cardiotoxicity with the assessment of doses to cardiac substructures such as LV or LAD. The LV segmentations and assignment of these segments to coronary arterial territories are still not sharply defined and confusing [32]. However, we are now collecting strain segmental values for each echocardiography of our patients and will further analyze this data according to the precise individual dose evaluation of each coronary artery [20]. On the other side, the strain is not uniform over the LV. The LV wall is not homogenous and comprises an endocardial, a mid-myocardial, and an epicardial layer [25]. Recent 2DSTE software allows separate evaluation of myocardial layers deformation [33]. Our measurements of longitudinal strain focused on individual evaluation of midwall deformations. Our results at baseline (GLS = −16.1 ± 2.7%) is consistent with the GLS observed in previous study [34]. Other studies averaged the three layers of GLS [11, 26], but we chose to focus here on the middle layer considering that this GLS would be a good indicator of the association with radiation exposure in the LV wall in addition to the fact that it has been shown in several studies to be robust and reproducible [24]. Further analysis detailing the three layers are in progress and may allow refining our results as previously observed for chemotherapy [35].

Research on radiation-induced changes in LV-function and association with cardiac exposure in patients treated with RT is not only relevant for BC patients. Patients treated for other organ with relevant heart doses like esophagus cancer, lung cancer or Hodgkin’s lymphoma are also of concerns. Some studies showed that, similarly to BC patients, these patients could receive high doses to the heart and its substructures [36] and GLS could be decreased after lung RT [37]. It is thus important to further develop studies, not only for BC patients, but also for other patients with thoracic RT.

Limitations

Even if we could observe associations between cardiac doses and the risk of subclinical LV dysfunction, our study showed the importance to consider also non-radiation factors such as BMI or endocrine therapy in the investigation of these association with doses as the results didn’t remain significant after adjustment. Our study is one of the largest ever published in this research area. However, with 79 patients, the size of the population involved a limited statistical power for odds ratios sub-analyses which may partly explain the absence of significant results in multivariate analysis. A large multicenter European study (MEDIRAD EARLY-HEART study) is ongoing and plan to include 250 patients which should provide results without this limitation [38]. Some alternatives to cardiac echocardiography for assessment of early cardiac damage exist, such as myocardial scintigraphy or cardiac magnetic resonance imaging. Myocardial scintigraphy is an important noninvasive method in the evaluation of patients with suspected coronary artery disease due to its high diagnostic accuracy, as well as being able to define the extent, severity and location of myocardial perfusion abnormalities. It is used for detecting ischemia in symptomatic patients, but its use in...
asymptomatic ones, like our BC patients, is less clear, which conducted us not to consider this examination in our cohort. However cardiac magnetic resonance imaging for assessment of the function and structure of the cardiovascular system is very promising and will be further investigated in MEDIRAD EARLY-HEART study [38]. The subclinical LV dysfunction defined as a GLS reduction > 10% is an indication of a beginning effect of radiation on LV function which corresponded to a secondary endpoint of BACCARAT study [21].

Conclusions
This is the first study to investigate the associations between BC RT-induced cardiac doses and subclinical LV dysfunction defined as a GLS reduction > 10%, 6 months after RT. This 6-month follow-up analysis indicated a significant association with mean heart dose, V20 of the heart, mean LV dose and V20 of the LV in univariate analysis. However, they didn’t remain significant in multivariate analysis in particular after adjustment for endocrine therapy. An exploratory analysis in our study allowed identifying a subgroup of patients (LV V20 > 15%) for whom a significant association with subclinical LV dysfunction was observed. LV dosimetry may be promising to identify high-risk subpopulations. Larger and longer follow-up studies are required to further investigate these associations.

Abbreviations
3D-CRT: 3 Dimensional Conformal Radiotherapy; BACCARAT: Breast Cancer and Cardiotoxicity Induced by Radiotherapy; BC: Breast Cancer; BMI: Body Mass Index; CT: Computed Tomography; DVH: Dose Volume Histogram; GLS: Global Longitudinal Strain; GLSR: Global Longitudinal Strain Rate; LS: Longitudinal Strain; LV: Left Ventricle; LVEF: Left Ventricle Ejection Fraction; MHD: Mean Heart Dose; RT: Radiotherapy; TPS: Treatment Planning System

Authors’ contributions
Conceived study: SJ, VW, OL, GJ, MOB, DL, JF. Data analysis: OL, OF, AP, BP, CC, DF, GJ, JC, LP, DB, SD, JF, SJ. Statistical analysis: VW, MOB, JF, DL, SJ. All authors participated in the writing, and manuscript edition. All authors read and approved the final manuscript.

Funding
The study received funding for collection of data from the Fédération Française de Cardiologie (FFC), from Electricité de France (EDF) and from the H2020 Euratom research and training program 2014–2018 under grant agreement No 755523 in the frame of the MEDIRAD project.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
This study received ethical approval from the French South West Committee for Protection of Persons (ID: CPP2015/66/2015-A00990–69) and from
National Agency for Medical and Health products Safety (Reference: 150873B-12). All patients enrolled in the study provided their written informed consent.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Laboratory of Epidemiology (LEPID), PSE-SANTE, SESANE, Institute for Radiological Protection and Nuclear Safety (IRSN), Fontenay-aux-Roses, France. 2Department of Cardiology, Clinique Pasteur, Toulouse, France. 3Department of Radiation Oncology (Oncorad), Clinique Pasteur, Toulouse, France. 4Department of Cardiac Arrhythmia, Clinique Pasteur, Toulouse, France. 5Department of Dosimetry, Institute for Radiological Protection and Nuclear Safety (IRSN), Fontenay-aux-Roses, France. 6Department of Cardiology, Clinique Pasteur, Toulouse, France. 7Department of Cardiology, Toulouse University Hospital, Toulouse, France. 8INSERM, UMR1027, Toulouse, France. 9Department of Cardiology, Clinique Pasteur, Toulouse, France. 3Department of Cardiology, Clinique Pasteur, Toulouse, France. 4Department of Cardiology, Clinique Pasteur, Toulouse, France. 5Department of Cardiology, Toulouse University Hospital, Toulouse, France. 6INGERA, UMR1027, Toulouse, France.

Received: 2 August 2019 Accepted: 28 October 2019
Published online: 14 November 2019

References
1. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Darby S, McGale P, Corea C, Taylor C, Arriagada R, Clarke M, Cuttner D, Davies C, Ewertz M, Godwin J, Gray R, Pierce L, Whelan T, Wang Y, Peto R. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials. Lancet. 2011;378:1707–16.
2. Clarke M, Collins R, Darby SC, Davies C, Elphinstone P, Evans V, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366:2087.
3. Darby SC, Ewertz M, McGale P, Bennet AW, Blom-Goldman U, Briennum D, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368:987–98.
4. Jacobsen JN, Duane FK, Boekel NB, Schaapveld M, Hauptmann M, Hooning MJ, et al. Radiation dose-response for risk of Myocardial infarction in Breast Cancer survivors. Int J Radiat Oncol Biol Phys. 2019;105:595–604.
5. van den Bogaard VAB, Ta BD, van der Schaaf A, Bourma AB, Middag AMH, Baatema-Joppe EJ, et al. Validation and modification of a prediction model for acute cardiac events in patients with breast Cancer treated with radiotherapy based on three-dimensional dose distributions to cardiac substructures. J Clin Oncol. 2017;35:1711–8.
6. Lancellotti P, Nikomo VT, Badano LP, Bergler-Klein J, Bogaert J, Davin L, et al. Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. Eur Heart J Cardiovasc Imaging. 2013;14:721–40.
7. Amundsen BH, Helle-Valle T, Edvardsen T, Torp H, Crosby J, Lyseggene E, et al. Noninvasive myocardial strain measurement by speckle tracking echocardiography. J Am Coll Cardiol. 2006;47:789–93.
8. Helle-Valle T, Crosby J, Edvardsen T, Lyseggene E, Amundsen BH, Smith H-J, et al. New noninvasive method for assessment of left ventricular rotation: speckle tracking echocardiography. Circulation. 2005;112:3149–56.
9. Kalam K, Othahal P, Marwick TH. Prognostic implications of global LV dysfunction: a systematic review and meta-analysis of global longitudinal strain and ejection fraction. Heart. 2014;100:1673–80.
10. Russo C, Jin Z, Eklind MSV, Rundek T, Homma S, Sacco RL, et al. Prevalence and prognostic value of subclinical left ventricular systolic dysfunction by global longitudinal strain in a community-based cohort. Eur J Heart Fail. 2014;16:1301–9.
11. Erven K, Jurcut R, Welten C, Giusca S, Ector J, Wildiers H, et al. Acute radiation effects on cardiac function detected by strain rate imaging in breast cancer patients. Int J Radiat Oncol Biol Phys. 2011;79:1444–51.
12. Erven K, Florian A, Slagmolen P, Sweldens C, Jurcut R, Wildiers H, et al. Subclinical cardiotoxicity detected by strain rate imaging up to 14 months after Breast radiation therapy. Int J Radiat Oncol Biol Phys. 2013;85:1172–8.
13. Heggemann F, Grotz H, Welzel G, Dosh C, Hansmann J, Kraus-Tiefenbacher U, et al. Cardiac function after multimodal breast cancer therapy assessed with functional magnetic resonance imaging and echocardiography imaging. Int J Radiat Oncol Biol Phys. 2015;93:3836–44.
14. Tuchinin SS, Skytta T, Poutanen T, Hultala H, Vitarianen V, Kellokumpu-Lehtinen P-L, et al. Radiotherapy-induced global and regional differences in early-stage left-sided versus right-sided breast cancer patients: speckle tracking echocardiography study. Int J Cardiovasc Imaging. 2017;33:463–72.
15. Lo Q, Hee L, Baturamali V, Allman C, MacDonald P, Lonergan D, et al. Strain imaging detects dose-dependent segmental cardiac dysfunction in the acute phase after breast irradiation. Int J Radiat Oncol Biol Phys. 2017;99:182–90.
16. Trivedi SJ, Choudhary P, Lo Q, Sritharan HP, Iyer A, Baturamali V, et al. Persistent reduction in global longitudinal strain in the longer term after radiation therapy in patients with breast cancer. Radiother Oncol. 2019;132:148–54.
17. Negishi K, Negishi T, Hare J, Haluska BA, Plana JC, Marwick TH. Independent and incremental value of deformation indices for prediction of Trastuzumab-induced Cardiotoxicity. J Am Soc Echocardiogr. 2013;26:493–9.
18. Thavendiranathan P, Poulin F, Lim K-D, Plana JC, Woo A, Marwick TH. Use of myocardial strain imaging by echocardiography for the early detection of Cardiotoxicity in patients during and after Cancer chemotherapy. J Am Coll Cardiol. 2014;63:2751–68.
19. Yu AF, Ho AY, Braunstein LZ, Thor ME, Lee Chuy K, Eaton A, et al. Assessment of early radiation-induced changes in left ventricular function by myocardial strain imaging after breast radiation therapy. J Am Soc Echocardiogr. 2019;32:521–8.
20. Jacob S, Camilleri J, Derneauaux S, Walker V, Lairez D, Lapeyre M, et al. Is mean heart dose a relevant surrogate parameter of left ventricle and coronary arteries exposure during breast cancer radiotherapy: a dosimetric evaluation based on individually-determined radiation dose (BACCARAT study). Radiat Oncol. 2019;14:29.
21. Jacob S, Pathak A, Frack D, Latorozell I, Gimenez F, Fondard O, et al. Early detection and prediction of cardiotoxicity after radiation therapy for breast cancer: the BACCARAT prospective cohort study. Radiat Oncol. 2016;11:54.
22. Gagliardi G, Coirstein LS, Moiseenko V, Corea F, Pierce LL, Allen AM, et al. Radiation Dose–Volume Effects in the Heart. Int J Radiat Oncol Biol Phys. 2010;76:577–85.
23. Voigt J-U, Pedrizetti G, Lysyansky P, Marwick TH, Houle H, Baumann R, et al. Definitions for a common standard for 2D speckle tracking echocardiography: consensus document of the EACVI/ASE/industry task force to standardize deformation imaging. J Am Soc Echocardiogr. 2015;28:183–93.
24. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography’s guidelines and standards committee and the chamber quantification writing group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18:1440–63.
25. Leitman M, Lyssiansky M, Lysyansky P, Friedman Z, Tyomin V, Fuchs T, et al. Circumferential and longitudinal strain in 3 myocardial layers in Normal subjects and in patients with regional left ventricular dysfunction. J Am Soc Echocardiogr. 2010;23:64–70.
26. Lo Q, Hee L, Baturamali V, Allman C, MacDonald P, Delaney GP, et al. Subclinical cardiac dysfunction detected by strain imaging during breast irradiation with persistent changes 6 weeks after treatment. Int J Radiat Oncol Biol Phys. 2015;92:268–76.
27. Sritharan HP, Delaney GP, Lo Q, Baturamali V, Xuan W, Thomas L. Evaluation of traditional and novel echocardiographic methods of cardiac diastolic dysfunction post radiotherapy in breast cancer. Int J Cardiol. 2017;243:204–8.
28. Matthews A, Stanway S, Farmer RE, Strongman H, Thomas S, Lyon AR, et al. Long term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors: systematic review. BMJ. 2018;363:k3845.
29. Lee K, Kruper L, Dieli-Convit WM, Mortimer JF. The impact of obesity on breast Cancer diagnosis and treatment. Curr Oncol Rep. 2019;21:41.
30. Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, et al. Expert consensus for multimodality imaging evaluation of adult patients
during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2014;15:1063–93.

31. Arciniegas Calle MC, Sandhu NP, Xia H, Cha SS, Pellikka PA, Ye Z, et al. Two-dimensional speckle tracking echocardiography predicts early subclinical cardiotoxicity associated with anthracycline-trastuzumab chemotherapy in patients with breast cancer. BMC Cancer. 2018;18:1037.

32. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Emande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the american society of echocardiography and the european association of cardiovascular imaging. J Am Soc Echocardiogr. 2015;28:1–39.e14.

33. Shi J, Pan C, Kong D, Cheng L, Shu X. Left ventricular longitudinal and circumferential layer-specific myocardial strains and their determinants in healthy subjects. Echocardiography. 2016;33:510–8.

34. Ancedy Y, Ederhy S, Lang S, Hollebecque A, Dufour LS, Adevane-Scheuble S, et al. Multilayer global longitudinal strain in patients with cancer: a comparison of two vendors. Arch Cardiovasc Dis. 2018;111:285–96.

35. Kang Y, Xiao F, Chen H, Wang W, Shen L, Zhao H, et al. Subclinical Anthracycline-induced Cardiotoxicity in the long-term follow-up of lymphoma survivors: a multi-layer speckle tracking analysis. Arq Bras Cardiol. 2018;110:219–28.

36. Shiraishi Y, Xu C, Yang J, Komaki R, Lin SH. Dosimetric comparison to the heart and cardiac substructure in a large cohort of esophageal cancer patients treated with proton beam therapy or intensity-modulated radiation therapy. Radiother Oncol. 2017;125:48–54.

37. Chen L, Ta S, Wu W, Wang C, Zhang Q. Prognostic and added value of echocardiographic strain for prediction of adverse outcomes in patients with locally advanced non-small cell lung cancer after radiotherapy. Ultrasound Med Biol. 2019;45:98–107.

38. Walker V, Crijns A, Langendijk J, Spoor D, Vliegenthart R, Combs SE, et al. Early detection of cardiovascular changes after radiotherapy for breast cancer: protocol for a European multicenter prospective cohort study (MEDIRAD EARLY HEART study). JMIR Res Protoc. 2018;7:e178.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.